Treatment of Parkinson's Disease: An Update
Supported by an unrestricted educational grant from:
Saturday, November 29, 2008
Rio de Janeiro, Brazil
Course Director
Francisco Eduardo C. Cardoso, MD, PhD
Belo Horizonte, Minas Gerais, Brazil
Faculty
Joaquim Jose C. Ferreira, MD - Torres Vedras, Portugal
Oscar S. Gershanik, MD - Buenos Aires, Argentina
Anthony E. Lang, MD, FRCPC - Toronto, ON, Canada
Andrew J. Lees, MD, FRCP - London, United Kingdom
Workshop Description
Parkinson's disease (PD) is a major neurological disorder that affects tens of millions of people worldwide. It is a chronic, progressive degenerative disorder of the central nervous system that leads to severe disability in many patients, and is a major healthcare issue, especially in the elderly. PD is caused by the loss of normal dopamine signalling in the brain, resulting in a range of characteristic movement, mobility and posture symptoms. This course will examine a variety of Parkison's disease therapies for all stages of the disease. Information will be provided in two ways: a didactic lecture setting with ample time for questions and answers, and workshop, case-based presentations to stimulate and amplify concepts presented in the early sessions.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Discuss the history of levodopa;
- Choose therapeutic options for symptomatic management of early stages of Parkinson's Disease;
- Describe the role of dopamine agonists in the management of Parkinson's Disease;
- Clinically manage levodopa-related motor complications;
- Treat psychosis and dementia in Parkinson's Disease;
- Describe the role of surgical treatment in Parkinson's Disease.
Recommended Audience
These workshops are intended for Movement Disorder specialists, general neurologists, primary care physicians and junior investigators.